Numbers look good to me, especially the pricing guidance for next quarter which beat my expectations given past history.
will continue holding as one of my biggest positions at an average of $3, awaiting the $20 party and beyond. This may be a good stock for a multi decade hold to let it compound whilst they build out their portfolio of assets and expand each into its 2nd and 3rd stages etc.
will have its ups and downs, but a nice diversified group tier 1 lowest quartile of cost curve assets, so should be able to ride the waves of the lithium cycle.
I think there is a fair chance we will hit $15 later this year as the fomo builds from both retail and institutions, especially now that ake is inside the asx100 and I suspect is widely under owned by the fund managers and super funds...they will have to accumulate some AKE to track the index.
- Forums
- ASX - By Stock
- AKE
- Ann: December Quarterly Activities Report
Ann: December Quarterly Activities Report, page-75
Featured News
Add AKE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online